Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs

Janos Szebeni*, Gert Storm

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

47 Citations (Scopus)

Abstract

Liposomes are known to activate the complement (C) system, which can lead in vivo to a hypersensitivity syndrome called C activation-related pseudoallergy (CARPA). CARPA has been getting increasing attention as a safety risk of i.v. therapy with liposomes, whose testing is now recommended in bioequivalence evaluations of generic liposomal drug candidates. This review highlights the adverse consequences of C activation, the unique symptoms of CARPA triggered by essentially all i.v. administered liposomal drugs, and the various features of vesicles influencing this adverse immune effect. For the case of Doxil, we also address the mechanism of C activation and the opsonization vs. long circulation (stealth) paradox. In reviewing the methods of assessing C activation and CARPA, we delineate the most sensitive porcine model and an algorithm for stepwise evaluation of the CARPA risk of i.v. liposomes, which are proposed for standardization for preclinical toxicology evaluation of liposomal and other nanoparticulate drug candidates.

Original languageEnglish
Pages (from-to)490-497
Number of pages8
JournalBiochemical and biophysical research communications
Volume468
Issue number3
DOIs
Publication statusPublished - 18 Dec 2015
Externally publishedYes

Keywords

  • Adverse drug reactions
  • Anaphylatoxins
  • Anaphylaxis
  • C5a
  • Complement
  • Pigs
  • Pseudoallergy

Fingerprint Dive into the research topics of 'Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs'. Together they form a unique fingerprint.

  • Cite this